The well-known businesswoman and Shark Tank India investor Namita Thapar is in the news once more. Her recent choice to sell off a portion of her ownership in Emcure Pharmaceuticals has shocked the business community. The return she expects to receive, which will be an astounding 293 times her initial investment, is what’s really amazing.
The Journey of Emcure Pharma
In the pharmaceutical industry, Pune-based Emcure Pharmaceuticals has been a shining success. Thapar has been associated with the firm since her initial days of investing. She owned 6,339,800 shares in Emcure, or 3.5% of the company. With a weighted average acquisition cost of Rs 3.44 for these shares, she invested a total of Rs 2.18 crore.
Both the Offer-for-Sale (OFS) and the IPO
In anticipation of Emcure Pharmaceuticals’ impending IPO, Thapar will be selling 1,268,600 shares in the OFS. The IPO’s price range is Rs 960 to Rs 1008 per share. Thapar will receive a return that, at the high end of this range, is an incredible 293 times her initial investment.
Additional Promoters and Their Profits
It’s not just Thapar who gains from Emcure’s prosperity. Satish Ramanlal Mehta and other promoters would also take part in the OFS. Mehta has a 41.85% ownership in 75,816,748 equity shares and may profit 52 times over his initial investment. A 3.63-fold profit will be realized by BC Investments IV.
Tables have turned and Shark Tank's Namita Thapar is pitching her company to you.
— NDTV Profit (@NDTVProfitIndia) July 1, 2024
Should you invest? @sajeetkm #EmcurePharmaIPO
Read: https://t.co/KjhCOtp6Yo pic.twitter.com/WjsDObSgBW
A Proof of Imagination and Persistence
Namita Thapar’s path, from her first investment to a 293x return, is proof of vision, perseverance, and the value of well-timed financial decisions. She leaves a motivating legacy for aspiring business owners and investors as she gets ready to depart Emcure Pharmaceuticals.
